Long Noncoding RNA DHRS4 Antisense RNA 1 Suppresses Osteosarcoma Cell Proliferation and Promotes Apoptosis Through a Competitive Endogenous RNA Mechanism

Overview

Journal Sci Rep

Date 2025 Jan 22

PMID 39843945

Authors

Zhouzhou Tang

Zhihao Li

Guofeng Wu

Jianjun Li

Jianye Tan

Lixin Zhu

Affiliations

Soon will be listed here.

Abstract

Osteosarcoma (OS) is the most common primary malignant bone tumor. Recent evidence suggests that the novel long noncoding RNA DHRS4 antisense RNA 1 (DHRS4-AS1) serves an important role in cancer progression and metastasis. However, its function and molecular mechanism in OS remain largely unknown. In the present study, DHRS4-AS1 expression was detected in OS cells by quantitative PCR. Gain- and loss-of-function experiments were conducted to study the effects of DHRS4-AS1 on the proliferation and apoptosis of OS cells. The potential mechanism of DHRS4-AS1 was examined through bioinformatics analysis and rescue experiments. DHRS4-AS1 was downregulated in OS cell lines. DHRS4-AS1 depletion promoted proliferation and inhibited apoptosis in OS cells, whereas DHRS4-AS1 overexpression had the opposite effects. Further research suggested that DHRS4-AS1 inhibited OS progression by regulating the microRNA-362-5p/aminopeptidase puromycin sensitive axis. The present findings suggested that DHRS4-AS1 may serve as a potential therapeutic target for OS.

References

Yang P, Ni F, Deng R, Qiang G, Zhao H, Yang M . MiR-362-5p promotes the malignancy of chronic myelocytic leukaemia via down-regulation of GADD45α. Mol Cancer. 2015; 14:190. PMC: 4636774. DOI: 10.1186/s12943-015-0465-3. View

Wu K, Yang L, Chen J, Zhao H, Wang J, Xu S . miR-362-5p inhibits proliferation and migration of neuroblastoma cells by targeting phosphatidylinositol 3-kinase-C2β. FEBS Lett. 2015; 589(15):1911-9. DOI: 10.1016/j.febslet.2015.05.056. View

Park J, Cheung N . Promise and Challenges of T Cell Immunotherapy for Osteosarcoma. Int J Mol Sci. 2023; 24(15). PMC: 10419531. DOI: 10.3390/ijms241512520. View

Luan F, Chen W, Chen M, Yan J, Chen H, Yu H . An autophagy-related long non-coding RNA signature for glioma. FEBS Open Bio. 2019; 9(4):653-667. PMC: 6443865. DOI: 10.1002/2211-5463.12601. View

Sadykova L, Ntekim A, Muyangwa-Semenova M, Rutland C, Jeyapalan J, Blatt N . Epidemiology and Risk Factors of Osteosarcoma. Cancer Invest. 2020; 38(5):259-269. DOI: 10.1080/07357907.2020.1768401. View

Chen J, Zhou J, Chen X, Yang B, Wang D, Yang P . miRNA-449a is downregulated in osteosarcoma and promotes cell apoptosis by targeting BCL2. Tumour Biol. 2015; 36(10):8221-9. DOI: 10.1007/s13277-015-3568-y. View

Chen C, Xie L, Ren T, Huang Y, Xu J, Guo W . Immunotherapy for osteosarcoma: Fundamental mechanism, rationale, and recent breakthroughs. Cancer Lett. 2020; 500:1-10. DOI: 10.1016/j.canlet.2020.12.024. View

Wei X, Wang B, Wang Q, Yang X, Yang Y, Fang Z . MiR-362-5p, Which Is Regulated by Long Non-Coding RNA MBNL1-AS1, Promotes the Cell Proliferation and Tumor Growth of Bladder Cancer by Targeting QKI. Front Pharmacol. 2020; 11:164. PMC: 7063466. DOI: 10.3389/fphar.2020.00164. View

Ren G, Ma Z, Hui M, Kudo L, Hui K, Karsten S . Cu, Zn-superoxide dismutase 1 (SOD1) is a novel target of Puromycin-sensitive aminopeptidase (PSA/NPEPPS): PSA/NPEPPS is a possible modifier of amyotrophic lateral sclerosis. Mol Neurodegener. 2011; 6:29. PMC: 3113298. DOI: 10.1186/1750-1326-6-29. View

10.

Matsunaga T, Endo S, Maeda S, Ishikura S, Tajima K, Tanaka N . Characterization of human DHRS4: an inducible short-chain dehydrogenase/reductase enzyme with 3beta-hydroxysteroid dehydrogenase activity. Arch Biochem Biophys. 2008; 477(2):339-47. DOI: 10.1016/j.abb.2008.06.002. View

11.

Zhou Y, Li K, Zou X, Hua Z, Wang H, Bian W . LncRNA DHRS4-AS1 ameliorates hepatocellular carcinoma by suppressing proliferation and promoting apoptosis via miR-522-3p/SOCS5 axis. Bioengineered. 2021; 12(2):10862-10877. PMC: 8809963. DOI: 10.1080/21655979.2021.1994719. View

12.

Wu F, Yin C, Qi J, Duan D, Jiang X, Yu J . miR-362-5p promotes cell proliferation and cell cycle progression by targeting GAS7 in acute myeloid leukemia. Hum Cell. 2020; 33(2):405-415. PMC: 7080691. DOI: 10.1007/s13577-019-00319-4. View

13.

Chen M, Wu X, Ma W, Zhou Q, Wang X, Zhang R . Decreased expression of lncRNA VPS9D1-AS1 in gastric cancer and its clinical significance. Cancer Biomark. 2017; 21(1):23-28. DOI: 10.3233/CBM-170172. View

14.

Utnes P, Lokke C, Flaegstad T, Einvik C . Clinically Relevant Biomarker Discovery in High-Risk Recurrent Neuroblastoma. Cancer Inform. 2019; 18:1176935119832910. PMC: 6413431. DOI: 10.1177/1176935119832910. View

15.

Yanagi K, Tanaka T, Kato K, Sadik G, Morihara T, Kudo T . Involvement of puromycin-sensitive aminopeptidase in proteolysis of tau protein in cultured cells, and attenuated proteolysis of frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17) mutant tau. Psychogeriatrics. 2010; 9(4):157-66. DOI: 10.1111/j.1479-8301.2010.00307.x. View

16.

Li Z, Wu X, Gu L, Shen Q, Luo W, Deng C . Long non-coding RNA ATB promotes malignancy of esophageal squamous cell carcinoma by regulating miR-200b/Kindlin-2 axis. Cell Death Dis. 2017; 8(6):e2888. PMC: 5520904. DOI: 10.1038/cddis.2017.245. View

17.

Huang D, Ichikawa Y . Purification and characterization of a novel cytosolic NADP(H)-dependent retinol oxidoreductase from rabbit liver. Biochim Biophys Acta. 1997; 1338(1):47-59. DOI: 10.1016/s0167-4838(96)00183-5. View

18.

Wang C, Wang G, Zhang Z, Wang Z, Ren M, Wang X . The downregulated long noncoding RNA is protumoral and associated with the prognosis of clear cell renal cell carcinoma. Onco Targets Ther. 2018; 11:5631-5646. PMC: 6141115. DOI: 10.2147/OTT.S164984. View

19.

Yang Y, Su Z, Song X, Liang B, Zeng F, Chang X . Enhancer RNA-driven looping enhances the transcription of the long noncoding RNA DHRS4-AS1, a controller of the DHRS4 gene cluster. Sci Rep. 2016; 6:20961. PMC: 4750091. DOI: 10.1038/srep20961. View

20.

Heymann M, Brown H, Heymann D . Drugs in early clinical development for the treatment of osteosarcoma. Expert Opin Investig Drugs. 2016; 25(11):1265-1280. DOI: 10.1080/13543784.2016.1237503. View